Introduction: Standing advances in neonatology increased survival of premature infants with the use of invasive procedures, which increases risk of infection and fungal sepsis. Risk factors for fungal sepsis are extensively studied. Candida is dominant, but there is increase in resistant C. non-albicans species. Mortality is high and requires timely suspicion of fungal sepsis, and adequate treatment to counteract the fatal outcome. Objectives: to analyze the clinical and laboratory characteristics of neonates, treated in the neonatal intensive care unit because of microbiologically proven fungal sepsis.
INTRODUCTION
Although fungal sepsis (FS) in Neonatal Intensive Care Unit (NICU) is less common than sepsis caused by Gram-positive and Gram-negative bacteria, it has a higher morbidity and mortality rate, especially in preterm infants with low birth weight, while infants who survive often have long-term neurological damage [1] . The mortality rate is different and ranges from 20-75% [2] . The risk factors for neonatal FS have been extensively studied and include prematurity, low birth weight, indwelling central venous chateter use, prolonged hospitalization, mechanical ventilation, endotracheal intubation, parenteral nutrition, prolonged broadspectrum antibiotic use, exposure to H2receptor antagonist, as well as previous Candida albicans colonization from mother [1] [2] [3] . Clinical presentations of FS have also been investigated as they are nonspecific in infants, and most commonly include thrombocytopenia, lethargy, glucose instability, increased requirements for ventilation or apnea [4] . It is very important for clinicians to be aware of constant risk of neonatal FS. Given the full extent of the problem, FS in critically ill infants should be considered with negative hemocultures, as early diagnosis and aggressive treatment improve overall outcome [5] [6] . The definite diagnosis of FS is not always easy to confirm because isolation and identification of the pathogen takes time, which makes it reasonable for infants with suspected FS to be treated empirically with antifungal therapy while awaiting for the results of micobiological findings. Empirical antifungal therapy is based on local epidemiology monitoring of dominant agents in a particular unit [7] [8] [9] .
Candida strains are most commonly reported as a causative agents of neonatal FS, but instead of the previously dominant (up to 80%) sensitive Candida albicans, a gradual increase in non-albicans Candida strains including C. parapsilosis, C.tropicalis i C. glabrata that show varying degrees of resistance to fluconazole and other antifungal agents have been reported [5] [6] [7] [8] [9] . Therefore, the recommended prophylactic administration of Fluconazole is questionable, and its routine, empirical administration as the first-line therapy may be inappropriate [2] . It is very important to have current information on neonatal fungal isolates and their patterns of antimicrobial susceptibility, and thus be guided in the choice of empirical antifungal therapy [10] [11] [12] [13] [14] .
The aim of this study was to determine the epidemiology of FS in Intensive Care Union of the Clinic for Children's Diseases, University Clinical Center Tuzla over a threeyear period, and to anlayze the clinical presentation and presence of the most common risk factors in infants with microbiologically confirmed FS. For comparative purposes, a systematic review of published studies on the epidemiology of FS in critically ill infants was used.
PATIENTS AND METHODS
A retrospective observational study included all consecutive infants with hemoculture confirmed FS from the total number of treated patients in Intensive Care Union (ICU) of the Clinic for Children's Diseases (capacity 20 beds, level III) in the period from 1 January 2016 to 31 December 2018. All infants who had at least one positive fungi hemoculture or signs and symptoms of infections were taken into consideration in this study. Only the first episode of FS had been reported for patients with recurrent positive findings. The study also included infants undergoing treatment and those who crossed the first 28 days following birth, so that all infants with hemoculture isolated fungi were included in this study.
Clinical and demographic data were obtained from medical records and electronic database of patients treated in ICU, which included gender, gestational age, birt weight and predisposing risk factor for FS (presence of central venous catheter, length of mechanical ventilation, antibiotic therapy, parenteral nutrition and length of hospitalization). During admission, clinical status of infants was scored by SNAP (Score for Neonatal Acute Physiology), SNAP-PE (Score for Neonatal Acute Physiology -Perinatal Extension) i CRIB(Clinical Risk Index for Babies) [15] .
The study was approved by Hospital's Ethics Committee. The long-term antibiotics use was considered if it exceeded 14 days of a continuos administration. Late neonatal sepsis is defined as an infection that develops after the first 7 days of life. Fluconazole was used as the first line of empirical antifungal therapy. There was no prophylactic administration of Fluconazole in neonatal unit at the time of the trial, and empiric antibiotic therapy for neonatal sepsis was Ceftazidime, Amikacin, which was corrected by Meropenem and/or Vancomycin, depending on further clinical course and findings in the particular patient.
For comparative purposes, a systematic review of published studies on the epidemiology of FS in critically ill patients was used. Standard methods of descriptive statistics (central tendency measures, dispersion measures) were used. Parametric and nonparametric significance tests (X²-test, Student's t-test) as well as linear correlation method were used to test the significance of differences between the samples. Statistical hypotheses were tested at a significance level of α=0.05, i.e. the difference between the samples is considered significant if P< 0.05. We used Systat Software, Systat Inc, Evanstan, IL, USA for statistical processing of data.
RESULTS
During the three-year period, 921 infants were treated in ICU, and their basic clinical and demographic characteristics are shown in Table 1 . Of total 921 treated infants, FS was found in 48 infants (5.2%), evenly found in both genders. The basic clinical and demographic data of infants treated for FS are shown in Table 2 . Mostly, it was about preterm infants with low birth weight with an average gestational age of 32.3±3.7 and birth weight of 1852±746 grams. Prematurity and low birth weight in our study were confirmed as the most significant perinatal risk factors for the development of fungal sepsis in critically ill infants Table 3 . Little significance in our stady had a vaginal birth. GW-gestational weeks; AS 1 st min-Apgar score in the first minute; AS 5 th minute-Apgar score in the fifth minute; PRM-premature rupture of membranes
The severity of illness in treated infants on admission was scored by neonatal tests (CRIB II and SNAPE-PE II), while the severe clinical picture of treated infants was confirmed by administered supportive therapy that was shown in Table 4 . All infants with fungal sepsis had an umbilical vein catheter, received parenteral nutrition and antibiotic therapy, and one fifth of them received prolonged a broad-spectrum antibiotic therapy. Almost 90% of them required mechanical ventilation support, and the mean ventilation support length was 8 days. Four infants underwent surgery for pneumothorax treatment. Of the other known risk factors for the development of FS, a quarter of our patients received H2-receptor blockers and had prolonged hospitalization. Clinically, fungal sepsis manifested as a late sepsis in all 48 patients, and the most common clinical presentation included respiratory deterioration, lethargy, feeding difficulties, and abdominal distension. (Table 5 ). Laboratory findings in neonates with fungal sepsis are shown in Table 6 . The most common deviation in our patients was presented as an increase in C-reactive protein and leukocytes with thrombocytopenia. (Table 7) . 
CRP-C reactive protein; Htc-hematocrit; ANC-Absolute neutrophil count
Fluconazole prophylaxis was not included at the time of the study, but Fluconazole therapy was included when there was a clinical suspicion of fungal sepsis and before the hemoculture findings were received. All hemoculture isolates were from the candida strains group without in-vitro resistance. The duration of Fluconazole therapy averaged 20.6±6 days; 11 of them received supportive platelet concentrate; 14 patients received intravenous gamaglobulin. Despite its in vitro sensitivity, Fluconazole was not effective in the treatment of two infants and it was replaced by Amphotericin B.
The outcome for 44 infants (91.7%) was favorable, while 4 infants (8.3%) died. The lenght of intensive care was 38.2± 23.2 days. The difference between infants survivors and deceased was found in the Apgar score result, that was more often statistically significant lower than 5 in deceased infants. Also, statistical significance was found in the length of intensive care that was significantly longer in survived infants. In 8 infants (16.7%) mild toxic hepatitis was recorded as a complication of the total treatment with transient enlargement of the liver, an increase in direct bilirubin and liver enzymes, which was successfully treated with supportive therapy and an oral ursodeoxycholic acid formulation.
DISCUSSION
Fungal sepsis (mainly Candida spp.) is an important cause of morbidity and mortality in critically ill infants [1] [2] [3] [4] [5] .Our study has shown that candidemia is a common probem in critically ill infants, with an overall incidence of 5.2%. This data is higher than those in the literatures of European countries reporting an incidence of 1.1-1.3% infants who were treated in intensive care union [3] [4] [5] [6] [7] [8] [9] , and North and South America reporting an incidence of 0.5-1.6% [10, 11] , but it is lower than published data in Asia reporting an incidence of 4-7.7% [12] [13] [14] . This variability may reflect differences in neonatal clinical practice among countries, as well as in the design of the study and patients involved in it. In our study, infants with fungal sepsis were evenly arranged by gender, which was generally in concord with the published literature, or it was reported a slight advantage of male infants [1] [2] [3] .
In nearly 90% of cases, it was about a preterm infants, while over 80% cases were with low birth weights, which was the most common result in published studies where dominated very immature infants (≤32 gestation weeks) and very low birth weight (≤1500 g) [1, 3, 5] . It is known that the risk for fungal sepsis in infants is high due to aggressive and invasive treatment, such as central venous catheters, mechanical ventilation, parenteral nutrition and prolonged hopitalization [16] . In our study all patients had an umbilical vein catheter, received parenteral nutrition and antibiotic therapy, and one-fifth of them received broad-spectrum antibiotic therapy. Almost 90% of them required mechanical ventilation, and the mean mechanical ventilation support length was 8 days. Intravenous catheters are risk factors for Candida sepsis in critically ill infants because Candida spp. can adhere to platelets and fibrinogen on the surface, form biofilms that can be a source for systemic infection [16] . Central venous catheters and parenteral nutrition are reported to be major risk for infection with non-albicans Candida strains, both of which predispose to the formation of catheter biofilms. Amino acids from parenteral nutrition mediate cell differentation,that could explain the high incidence of Candida in neonates with a central venous catheter receiving amino acid-rich parenteral diet [16] .
Most of our patients (89.6%) were on mechanical ventilation support. Mechanical ventilation has been described as a risk factor for neonatal fungal sepsis, although there are also very rare reports describing non-invasive support with cotinuous positive airway pressure as a risk factor [2] . Four infants in our study underwent surgery for pneumothorax treatment.
Other studies report a significantly higher proportion of surgical intervention in infants with fungal sepsis up to 44% [2] , including necrotizing enterocolitis up to 25%. Candida sepsis has been described as an uncommon cause of intenstinal perforation and necrotizing enterocolitis [2] , and abdominal surgery has been reported as a risk factor for the onset of Candida sepsis regardless of birth weight [2] .
Fungal sepsis manifested as late neonatal sepsis in all patients, which is the most common result in other studies, and only rarely Canida is reported as the cause of early neonatal sepsis [17] . Clinical presentation in our study included respiratory deterioration, lethargy, feeding difficulties and distension of the abdomen, which is also consistent with reports from other studies [13] . The most common laboratory results deviation in our patients were an increase in C-reactive protein, leukocytes and thrombocytopenia [13] . All hemoculture isolates in our study were from Candida spp. group without in vitro resistance, which is consistent with some published studies [1] [2] [3] . There are regional differences in the incidence of the most common Candida strains. Through a systematic literature review, we found out that four Candida species (C. albicans, C. parapsilosis complex, C. tropicalis i C. glabrata complex) are associated with more than 95% cases of neonatal candidemia, but the distribution of these four species is different. In general, Candida albicans was the dominant isolated strain in Europe [3] [4] [5] [6] [7] [8] [9] and North and South America [10] [11] , and non-albicans strains were dominant in Asia [12] [13] [14] . However, more recent studies report constant growth of Candida non-albicans strains, with a frequency higher than 50% in some neonatal intensive care unions. This is partly associated with an increase in clinical use of the azole antifungal therapy and prophylaxis [18] [19] [20] , although this has also been reported in hospitals where Fluconazole has rarely been used for prophylaxis and therapy [3] . Even some earlier reports, such as the Helsinki report [21] mention the emergence of Fluconazole resistance in a C. parapsilosis strain after more than 10 years of Fluconazole prophylaxis in neonatal intensive care unions. There was a high incidence of Fluconazole resistance in C. parapsilosis in this study, so that routine use of Fluconazole prophylaxis in this constellation is questionable. The outcome for infants (91.7%) in this study was favorable, while 4 infants (8.3%) died. Mortality rate due to neonatal fungal sepsis varied, and it is mostly high. It goes from 40% [2,-] up to 75% [22] , and is considered low if it is below 20% [23].The difference between survivors and deceased in our study was found only for the Apgar score and the length of intensive care. Mortality in other studies are mainly related to known risk factors and their correlation.
CONCLUSION
Candida sepsis is an important cause of morbidity and mortality in critically ill infants. The incidence at our hospital is 5.2 per 100 admissions to Neonatal Intensive Care Union. Perinatal risk factors for fungal sepsis are prematurity and low birth weight. The umbilical vein catheter, parenteral nutrition, antibiotic therapy and mechanical ventilation are also considered to be significant risk factors.
